Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pmc-release:
26
10
2020
pubmed:
3
5
2019
medline:
16
6
2021
entrez:
3
5
2019
Statut:
ppublish
Résumé
Monophosphoryl lipid A (MPLA) is a TLR4 agonist that has potent immunomodulatory properties and modulates innate immune function to improve host resistance to infection with common nosocomial pathogens in mice. The goal of this study was to assess the safety and efficacy of MPLA in a sheep model of burn injury and Pseudomonas aeruginosa pneumonia. The sheep provides a favorable model for preclinical testing as their response to TLR4 agonists closely mimics that of humans. Twelve chronically instrumented adult female Merino sheep received 20% total body surface area, third-degree cutaneous burn under anesthesia and analgesia. At 24 h after burn, sheep were randomly allocated to receive: MPLA (2.5 μg/kg i.v., n = 6), or vehicle (i.v., n = 6). At 24 h after MPLA or vehicle treatment, Pseudomonas aeruginosa pneumonia was induced. Sheep were mechanically ventilated, fluid resuscitated and cardiopulmonary variables were monitored for 24 h after induction of pneumonia. Cytokine production, vascular barrier function, and lung bacterial burden were also measured. MPLA infusion induced small and transient alterations in core body temperature, heart rate, pulmonary artery pressure, and pulmonary vascular resistance. Pulmonary mechanics were not altered. Vehicle-treated sheep developed severe acute lung injury during Pseudomonas aeruginosa pneumonia, which was attenuated by MPLA as indicated by improved PaO2/FiO2 ratio, oxygenation index, and shunt fraction. Sheep treated with MPLA also exhibited less vascular leak, lower blood lactate levels, and lower modified organ injury score. MPLA treatment attenuated systemic cytokine production and decreased lung bacterial burden. MPLA was well tolerated in burned sheep and attenuated development of acute lung injury, lactatemia, cytokinemia, vascular leak, and hemodynamic changes caused by Pseudomonas aeruginosa pneumonia.
Sections du résumé
BACKGROUND
Monophosphoryl lipid A (MPLA) is a TLR4 agonist that has potent immunomodulatory properties and modulates innate immune function to improve host resistance to infection with common nosocomial pathogens in mice. The goal of this study was to assess the safety and efficacy of MPLA in a sheep model of burn injury and Pseudomonas aeruginosa pneumonia. The sheep provides a favorable model for preclinical testing as their response to TLR4 agonists closely mimics that of humans.
METHODS
Twelve chronically instrumented adult female Merino sheep received 20% total body surface area, third-degree cutaneous burn under anesthesia and analgesia. At 24 h after burn, sheep were randomly allocated to receive: MPLA (2.5 μg/kg i.v., n = 6), or vehicle (i.v., n = 6). At 24 h after MPLA or vehicle treatment, Pseudomonas aeruginosa pneumonia was induced. Sheep were mechanically ventilated, fluid resuscitated and cardiopulmonary variables were monitored for 24 h after induction of pneumonia. Cytokine production, vascular barrier function, and lung bacterial burden were also measured.
RESULTS
MPLA infusion induced small and transient alterations in core body temperature, heart rate, pulmonary artery pressure, and pulmonary vascular resistance. Pulmonary mechanics were not altered. Vehicle-treated sheep developed severe acute lung injury during Pseudomonas aeruginosa pneumonia, which was attenuated by MPLA as indicated by improved PaO2/FiO2 ratio, oxygenation index, and shunt fraction. Sheep treated with MPLA also exhibited less vascular leak, lower blood lactate levels, and lower modified organ injury score. MPLA treatment attenuated systemic cytokine production and decreased lung bacterial burden.
CONCLUSIONS
MPLA was well tolerated in burned sheep and attenuated development of acute lung injury, lactatemia, cytokinemia, vascular leak, and hemodynamic changes caused by Pseudomonas aeruginosa pneumonia.
Identifiants
pubmed: 31045990
doi: 10.1097/SHK.0000000000001364
pmc: PMC6937402
mid: NIHMS1028336
pii: 00024382-202003000-00008
doi:
Substances chimiques
Adjuvants, Immunologic
0
Lipid A
0
monophosphoryl lipid A
MWC0ET1L2P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-316Subventions
Organisme : NIGMS NIH HHS
ID : K08 GM117367
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121711
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM108554
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM104306
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007347
Pays : United States
Organisme : NIGMS NIH HHS
ID : K08 GM123345
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM119197
Pays : United States
Références
J Immunol. 2018 Jun 1;200(11):3777-3789
pubmed: 29686054
Circ Shock. 1979;6(1):13-21
pubmed: 378454
Surg Clin North Am. 2014 Aug;94(4):781-91
pubmed: 25085088
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069
Infect Control Hosp Epidemiol. 2014 May;35(5):597-9
pubmed: 24709737
Infect Immun. 2011 Sep;79(9):3576-87
pubmed: 21646453
Microb Drug Resist. 2017 Oct;23(7):852-863
pubmed: 28437232
Biochem Biophys Res Commun. 2010 Jan 15;391(3):1555-60
pubmed: 20036639
BMJ. 2016 May 17;353:i2375
pubmed: 27189000
Biologics. 2008 Mar;2(1):97-105
pubmed: 19707432
Am J Infect Control. 2003 Oct;31(6):342-6
pubmed: 14608300
J Immunol. 2017 Apr 15;198(8):3264-3273
pubmed: 28275139
Free Radic Biol Med. 2007 May 1;42(9):1421-9
pubmed: 17395015
Trends Mol Med. 2014 Apr;20(4):195-203
pubmed: 24581450
Clin Microbiol Infect. 2012 Jan;18(1):54-60
pubmed: 21722257
Clin Sci (Lond). 2016 Mar;130(6):451-61
pubmed: 26669797
Burns. 2005 Dec;31(8):1013-9
pubmed: 16288960
Crit Care Med. 1995 Jan;23(1):9-17
pubmed: 8001393
Crit Care. 2009;13(6):R183
pubmed: 19919684
Burns. 2014 Aug;40(5):835-41
pubmed: 24296064
Infect Immun. 2001 Sep;69(9):5249-63
pubmed: 11500393
Shock. 2013 Dec;40(6):451-62
pubmed: 23989337
J Hosp Infect. 2017 Oct;97(2):105-114
pubmed: 28629932
Am J Physiol. 1988 May;254(5 Pt 2):H833-9
pubmed: 3364588
Am J Infect Control. 2016 Dec 1;44(12):1495-1504
pubmed: 27742143
Crit Care Med. 2015 Feb;43(2):282-7
pubmed: 25377018
Innate Immun. 2015 Aug;21(6):565-74
pubmed: 25540284
Clin Infect Dis. 2008 Oct 1;47(7):927-30
pubmed: 18752440
J Leukoc Biol. 2016 Apr;99(4):629-40
pubmed: 26538529
PLoS One. 2015 Dec 07;10(12):e0144345
pubmed: 26640957
J Endotoxin Res. 2004;10(2):71-84
pubmed: 15119998
Transl Res. 2017 Feb;180:53-67.e4
pubmed: 27567430
Crit Care Med. 2016 Feb;44(2):e89-96
pubmed: 26465218
Cochrane Database Syst Rev. 2013 Jun 06;(6):CD008738
pubmed: 23740764
Sci Rep. 2017 Jan 05;7:40050
pubmed: 28053314
J Leukoc Biol. 2016 Dec;100(6):1311-1322
pubmed: 27354411
Burns. 1999 Nov;25(7):611-6
pubmed: 10563687
Antimicrob Agents Chemother. 2012 Mar;56(3):1265-72
pubmed: 22155832
Pol Przegl Chir. 2012 Jan;84(1):6-16
pubmed: 22472489
Cancer Discov. 2011 Oct;1(5):377-80
pubmed: 22586628
BMJ. 2010 Feb 15;340:c241
pubmed: 20156911
Virulence. 2014 Jan 1;5(1):4-11
pubmed: 24335434
JAMA. 2011 Dec 21;306(23):2614-5
pubmed: 22187284
EBioMedicine. 2015 Jul 31;2(10):1536-48
pubmed: 26629550
Crit Care. 2009;13(1):R19
pubmed: 19222851
JAMA. 2016 Apr 12;315(14):1457-9
pubmed: 26975243
Shock. 2008 May;29(5):642-9
pubmed: 17885644
Shock. 2002 Dec;18(6):561-6
pubmed: 12462566
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Immunobiology. 1993 Apr;187(3-5):330-45
pubmed: 8330902
Infect Immun. 1990 Aug;58(8):2429-37
pubmed: 1695201
J Transl Med. 2017 Dec 28;15(1):266
pubmed: 29282084
Shock. 2011 Nov;36(5):466-70
pubmed: 21921834
Emerg Infect Dis. 2001 Mar-Apr;7(2):174-7
pubmed: 11294700